Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-37762
Titel: | Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study |
VerfasserIn: | Erlmeier, Franziska Steffens, Sandra Stöhr, Christine Herrmann, Edwin Polifka, Iris Agaimy, Abbas Trojan, Lutz Ströbel, Philipp Becker, Frank Wülfing, Christian Barth, Peter Stöckle, Michael Staehler, Michael Stief, Christian Haferkamp, Axel Hohenfellner, Markus Macher-Göppinger, Stephan Wullich, Bernd Noldus, Joachim Brenner, Walburgis Roos, Frederik C. Walter, Bernhard Otto, Wolfgang Burger, Maximilian Schrader, Andres Jan Hartmann, Arndt Ivanyi, Philipp |
Sprache: | Englisch |
Titel: | Clinical Genitourinary Cancer |
Bandnummer: | 19 (2021) |
Heft: | 1 |
Seiten: | 53-59.e1 |
Verlag/Plattform: | Elsevier |
Erscheinungsjahr: | 2020 |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 were evaluable for PD-1 and PD-L1 expression analysis. In total, PD-1 and PD-L1 expression were found in 8 (4.9%) of 162 and 12 (7.2%) of 166 evaluable pRCC type 1 specimens. Comparably, PD-1 and PD-L1 expression were found in 2 (2.4%) of 83 and 5 (6.2%) of 81 evaluable pRCC type 2 specimens. Hardly any clinically relevant associations between PD-1 and PD-L1 positivity and clinicopathologic or clinical courses were observed, neither in pRCC type 1 nor type 2. Conclusion The analysis of a large pRCC cohort from a multicenter consortium revealed no impact of PD-1/PD-L1 expression on prognosis in patients with pRCC with predominantly limited disease status, neither for type 1 nor type 2. However, the impact of PD-1 and PD-L1 in more advanced pRCC disease needs further elucidation. |
DOI der Erstveröffentlichung: | 10.1016/j.clgc.2020.07.002 |
URL der Erstveröffentlichung: | https://www.sciencedirect.com/science/article/abs/pii/S155876732030149X |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-377624 hdl:20.500.11880/34157 http://dx.doi.org/10.22028/D291-37762 |
ISSN: | 1558-7673 |
Datum des Eintrags: | 28-Okt-2022 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Urologie und Kinderurologie |
Professur: | M - Prof. Dr. Michael Stöckle |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.